A California beauty company and its South Korean partner are lobbying the Trump administration to ensure their rival to the Botox wrinkle treatment doesn’t get frozen out of the U.S. market.
Evolus Inc. and its partner Daewoong Pharmaceutical Co. have been reaching out over the past two months to President Donald Trump and his administration to overrule a possible U.S. import ban on their treatment, called Jeuveau, which is manufactured in South Korea.
Evolus Lobbies Trump to Avoid U.S. Ban on its Botox Alternative
